Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01469338
Other study ID # 4P-11-3
Secondary ID NCI-2011-03266
Status Terminated
Phase Phase 2
First received November 1, 2011
Last updated November 21, 2014
Start date July 2012
Est. completion date November 2014

Study information

Verified date November 2014
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well octreotide works in reducing diarrhea in patients receiving cabazitaxel and prednisone for hormone-resistant prostate cancer (HRPC) previously treated with docetaxel. Octreotide may prevent diarrhea by blocking the secretion of several hormones in patients receiving chemotherapy for prostate cancer


Description:

PRIMARY OBJECTIVES:

I. To evaluate the impact of octreotide in reducing the incidence of grade 2 or greater diarrhea in men receiving cabazitaxel plus prednisone for castration-resistant prostate cancer (CRPC) after docetaxel therapy.

SECONDARY OBJECTIVES:

I. Overall survival (OS).

II. Progression-free survival (PFS) (defined as the time between treatment start and the first date of progression as measured by objective tumor progression using the Response Evaluation Criteria In Solid Tumors (RECIST), pain progression or death).

III. Prostate-specific antigen (PSA) response rate.

IV. Objective response rate.

V. Pain response.

VI. Toxicity.

OUTLINE:

Patients receive cabazitaxel as intravenous (IV) infusion over 1 hour on day 1, prednisone by mouth (PO) every day (QD), and octreotide pamoate given as intramuscular (IM) injection on day 1. Patients also receive octreotide acetate as a subcutaneous (SC) injection three times a day (TID) on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 1 month, every 3 months until disease progression, and then every 6 months thereafter.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date November 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed prostate cancer

- Measurable disease on computed tomography (CT) or evaluable disease with an elevated PSA

- Documented progression on (a) at least one prior hormone treatment, which must have incorporated luteinizing hormone-releasing hormone (LHRH) agonist therapy AND (b) at least one chemotherapy regimen, which must have included docetaxel; progression may be demonstrated by radiologic criteria or by PSA only if accompanied by new or worsening symptoms (pain progression)

- Eastern Cooperative Oncology Group (ECOG) performance score of 0-2

- Absolute neutrophil count (ANC) more than or equal to 1500/ul

- Hemoglobin more than or equal to 8.0 g/dL

- Platelet count more than or equal to 100,000/ul

- Serum creatinine less than or equal to 1.5x the upper limit of normal (ULN)

- Bilirubin less than or equal to ULN

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 1.5x ULN

- Must be recovered from acute and late effects of any prior surgery, radiotherapy or other anti-neoplastic therapy

- Patients or their legal representatives must be able to read, understand, and provide informed consent

- Men of childbearing potential must consent to use barrier contraception while on treatment and for 90 days thereafter

- Palliative radiation for metastatic disease is allowed if less or equal to 40% of the total bone marrow was irradiated; 28 days must have elapsed since completion of radiation therapy (RT) with bone marrow recovery; soft tissue disease irradiated in the prior 2 months may not be designated as measurable disease

- Concomitant bisphosphonate use is permitted if the dose had been stable for 12 weeks prior to enrollment

Exclusion Criteria:

- Treatment with radiotherapy, chemotherapy or any investigational agent in the prior 4 weeks

- Major surgery in the prior 4 weeks

- Prior treatment with cabazitaxel

- Patients with known hypersensitivity to cabazitaxel, other drugs formulated with polysorbate 80 or octreotide

- Inability to tolerate oral prednisone

- Grade 2 or greater diarrhea in the prior 2 weeks

- Grade 2 or greater neuropathy or stomatitis

- Presence of an active uncontrolled infection or fever greater or equal to 38.5 degrees

- Presence of parenchymal brain metastases; patients with neurological symptoms must have a CT or magnetic resonance imaging (MRI) of the brain showing no metastases within 60 days of enrollment

- Prior malignancy within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or superficial bladder or other stage I or stage II cancer in complete remission for at least 12 months

- History of unstable or newly diagnosed angina pectoris, documented history of current serious arrhythmia or congestive heart failure (CHF) or recent myocardial infarction (MI)within 6 months of enrollment

- Known human immunodeficiency virus (HIV) or hepatitis infection

- Life expectancy less than 3 months

- Presence of any other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with interpretation of the results

- Lack of ability/willingness to give informed consent

- Lack of ability/willingness to receive octreotide injection

- Anticipated non-availability for study visits/procedures

- Patients with uncontrolled diabetes, defined as a HbA1c greater than 7% or greater or equal to 8% despite therapy, or a fasting plasma glucose more than 2x ULN; at the investigator's discretion, non-eligible patients can be re-screened after adequate medical therapy has been instituted

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Intervention

Drug:
cabazitaxel
Given IV
prednisone
Given PO
octreotide pamoate
Given IM
Other:
questionnaire administration
Ancillary studies
Drug:
octreotide acetate
Given SC

Locations

Country Name City State
United States USC/Norris Comprehensive Cancer Center Los Angeles California

Sponsors (3)

Lead Sponsor Collaborator
University of Southern California National Cancer Institute (NCI), Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Development of Grade 2 plus diarrhea Defined by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 criteria as an increase in frequency of 4 or greater stools per day over baseline, incontinence, diarrhea warranting hospitalization or diarrhea limiting self-care activities of daily living (ADL). Baseline frequency will be defined in the pre-treatment assessment from cycle 1 as the maximum number of stools in one 24 hour period during the past 2 weeks. Any incidence of grade 2 or greater diarrhea during treatment or for up to 21 days after the last administration of cabazitaxel will be included in this endpoint. Baseline through 21 days after the last administration of cabazitaxel No
Secondary Progression-Free Survival At 1 month after completion of treatment, every 3 months until disease progression, and then every 6 months thereafter No
Secondary Overall Survival At 1 month after completion of treatment, every 3 months until disease progression, and then every 6 months thereafter No
Secondary RECIST response for patients with measurable disease Baseline, after every 4 courses, at the end of treatment, and then every 6 months No
Secondary Prostate-Specific Antigen response Baseline, day 1 of each course, at the end of treatment, and then every 6 months No
Secondary Pain palliation in patients with a baseline pain score greater or equal to 2 Baseline, day 1 of each 3 week course, at the end of treatment, and then every 6 months for up to 52 weeks No
Secondary Toxicity (adverse events considered to be at least possibly drug-related) Baseline, day 1 of each course, and at the end of treatment Yes
See also
  Status Clinical Trial Phase
Completed NCT06283784 - Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients N/A
Recruiting NCT03851835 - Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis Phase 3
Completed NCT04003181 - The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon N/A
Completed NCT03596827 - The Protective Immune Response to Attenuated Enterotoxigenic Escherichia Coli Infection N/A
Recruiting NCT05372068 - Cement flooRs AnD chiLd hEalth (CRADLE) N/A
Completed NCT03972618 - Evaluation of the Efficacy of Sawyer Point One Filters in Schools and Homes in the Dominican Republic N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT05052489 - Registry and Clinical Observation of Children With Diarrhoeal Disease
Completed NCT02428647 - Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation N/A
Completed NCT02541695 - Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli N/A
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT01968408 - Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children Phase 3
Completed NCT01739231 - Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults Phase 1/Phase 2
Terminated NCT01472211 - Water-based Zinc Intervention Trial in Zinc Deficient Children Phase 0
Completed NCT01438645 - ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy N/A
Completed NCT01371656 - Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Phase 3
Not yet recruiting NCT01382199 - Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients Phase 3
Terminated NCT01048567 - Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly Phase 2
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT00760851 - Yogurt Study in Children 2-4 Years Old Attending Daycare Phase 3